•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
Changes recommended in clinical trial design to include the voice of more people living with type 1 diabetes in evaluating therapy benefits
NEW YORK, Aug....
The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...
The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
The market for B7-H4 targeted therapies is projected to experience substantial growth in the coming years, driven by a rising incidence of cancer diagnoses,...
Latest Research Demonstrates Promising Improved Glucose Homeostasis by Reprogramming Alpha Cells
AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a...
Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes
CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes